2. Search Result
Search Result
Results for "

RNA binder

" in MedChemExpress (MCE) Product Catalog:

15

Inhibitors & Agonists

1

Peptides

1

Oligonucleotides

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-124447
    BTYNB

    		IGF-1R c-Myc Apoptosis TGF-beta/Smad Cancer
    BTYNB is a structure-specific nucleic acid binder and IGF2BP1 inhibitor (with an IC50 of 5 μM against hBTYNB). BTYNB disrupts the IGF2BP1-RNA interaction and blocks its binding to oncogenic mRNAs such as c-Myc, MDM2, PD-L1. BTYNB completely blocks the INHBA-Smad2/3 pathway, disrupts the MYCN/IGF2BP1 loop, and thereby induces apoptosis and cell cycle arrest, effectively inhibiting the proliferation and survival of cancer cells. In addition, BTYNB acts as an immune activator and tumor microenvironment modulator, enhances T cell-mediated tumor killing, and produces significant synergistic effects with inhibitors of PD-1, BRD and BIRC5. BTYNB can be used in relevant research on various malignant tumors including ovarian cancer, neuroblastoma, leukemia and melanoma .
    BTYNB
  • HY-153713
    MYC-RIBOTAC
    1 Publications Verification

    		 RIBOTAC c-Myc Apoptosis Cancer
    MYC-RIBOTAC is a nucleic acid-targeting degrader (ribonuclease-targeting chimera, RIBOTAC) that targets the MYC internal ribosome entry site (IRES). MYC-RIBOTAC contains a MYC mRNA binding component and a small molecule that recruits and locally activates RNAse L1. MYC-RIBOTAC reduces MYC mRNA and protein expression levels, induces cell apoptosis, and can be used for antitumor research . MYC-RIBOTAC consists of pre-miR-155 binder Anticancer agent 167 (HY-156839), RNA binder NCI-B16 (HY-156215), and Linker Amino-PEG4-alcohol (HY-W008005).
    MYC-RIBOTAC
  • HY-173189A
    2-5A pentasodium solution (100 mM)

    2′,5′-ApApA pentasodium; 2′,5′-trioligoadenylate pentasodium; 5'-O-Triphosphoryladenylyl-(2'→5')-adenylyl-(2'→5')-adenosine pentasodium

    		 RSV DNA/RNA Synthesis Infection Cancer
    2-5A (2′,5′-ApApA) pentasodium solution 100 mM is a high-affinity (Ka=0.04 nM) RNase L binder. 2-5A pentasodium solution 100 mM activates the nuclease activity of latent RNase L to cleave single-stranded RNA by inducing conformational changes and dimerization of latent RNase L, thereby mediating critical antiviral responses and enhancing interferon effects. 2-5A pentasodium solution 100 mM not only effectively inhibits Rauscher murine leukemia virus replication, reduces viremia and splenomegaly, but also enhances antileukemic efficacy when combined with amphotericin B and exhibits favorable high-dose tolerance. 2-5A pentasodium solution 100 mM is an important tool molecule for investigating the pathological mechanisms of viral infection, hereditary prostate cancer and leukemia .
    2-5A pentasodium solution (100 mM)
  • HY-153898
    rTRD01

    		Amyloid-β Neurological Disease
    rTRD01 is an orally active, specific TDP-43 binder that targets the RRM1 and RRM2 domains of TDP-43. rTRD01 partially disrupts the interaction between TDP-43 and c9orf72 repeat RNA, but does not affect the binding of TDP-43 to canonical binding sequences. rTRD01 exhibits significant neuroprotective effects in zebrafish models, improves motor function and protects against paraquat (a widely used herbicide)-induced neurodegeneration, with no teratogenicity at high concentrations. rTRD01 is not a general antioxidant and cannot counteract Rotenone (HY-B1756)-induced neuronal death. rTRD01 can be used to study amyotrophic lateral sclerosis and other TDP-43 proteinopathies .
    rTRD01
  • HY-156215
    NCI-B16

    		HCV Infection
    NCI-B16 is a small molecule RNA binder and inhibits HCV viral replication .
    NCI-B16
  • HY-W141374
    CB096

    		DNA/RNA Synthesis Neurological Disease
    CB096 is an r(G4C2) exp RNA binder with EC50 values of 19 μM, 20 μM and 33 μM. CB096 selectively interacts with the 5′CGG/3′GGC 1×1 GG internal loop motif of folded r(G4C2) exp RNA, alters motif dynamics and closed base pairs, and rescues disease-related pathways. CB096 can be used for research on inherited amyotrophic lateral sclerosis/frontotemporal dementia (c9ALS/FTD) .
    CB096
  • HY-174226
    RNA binder 2

    		DNA/RNA Synthesis Others
    RNA binder 2 (Compound 20) is a covalent inhibitor targeting the r(CUG)exp RNA in myotonic dystrophy type 1 (DM1). RNA binder 2 binds to RNA via a Hoechst scaffold, blocking MBNL1 binding and restoring normal splicing. RNA binder 2 is promising for research of DM1 .
    RNA binder 2
  • HY-177031
    RNA binder 3

    		RIBOTAC DNA/RNA Synthesis Others
    RNA binder 3 is an RNA binder that can be used in the synthesis of RiboTAC F3-PEG8-RiboTAC (HY-176259) .
    RNA binder 3
  • HY-172902
    RNA binder 1

    		DNA/RNA Synthesis Neurological Disease
    RNA binder 1 (Compound 4b) is a blood-brain permeable RNA binder. RNA binder 1 can selectively bind to the G-quadruplex structure of the G4C2 repeat sequence RNA of the C9orf72 gene. RNA binder 1 significantly reduces the levels of toxic polypeptides poly(GA) and poly(GP) produced by the G4C2 repeat sequence in amyotrophic lateral sclerosis (ALS) patient-derived cells. RNA binder 1 has no significant effect on the antisense polypeptide poly(PR), showing selectivity for sense RNA. RNA binder 1 can be used in the study of ALS and frontotemporal dementia (FTD) .
    RNA binder 1
  • HY-176259
    F3-PEG8-RiboTAC

    		RIBOTAC Apoptosis Galectin Cancer
    F3-PEG8-RiboTAC is a RiboTAC that can specifically degrade the mRNA of the oncogene LGALS1. F3-PEG8-RiboTAC can induce tumor cell apoptosis and inhibit invasion. F3-PEG8-RiboTAC has anti-tumor activity and can be used in the research of tumors such as leukemia and triple-negative breast cancer. (RNase L ligand (HY-177030); RNA binder (HY-177031); Linker (HY-W019798)) .
    F3-PEG8-RiboTAC
  • HY-169497
    MTDB

    		Drug Intermediate Others
    MTDB is a synthetic intermediate in the synthesis of the clickable RNA pseudoknot binder MTDB-Alkyne.
    MTDB
  • HY-146382
    WRNA10

    		HIV Inflammation/Immunology
    WRNA10 is a potent HIV-1 TAR RNA binder with an IC50 of 10 µM and an CC50 of 40 µM .
    WRNA10
  • HY-179344
    Benzazepinoquinoline-spermine

    		MicroRNA Cancer
    Benzazepinoquinoline-spermine (Compound PA-3) is an efficient pre-miR-372 complexing agent, and it can specifically inhibit its processing mediated by Dicer. Its IC₅₀ value is 0.58 μM. Benzazepinoquinoline-spermine has a strong affinity for pre-miR-372, with a KD value of 0.11 μM. Benzazepinoquinoline-spermine also shows high activity against pre-miR-373 (IC₅₀ = 0.29 μM), but significantly reduced inhibitory activity against pre-miR-17, pre-miR-21, and pre-miR-155 (IC₅₀ being 0.84 μM, 1.43 μM, and 1.07 μM respectively). Benzazepinoquinoline-spermine can be used for cancer research .
    Benzazepinoquinoline-spermine
  • HY-183761
    Antiviral agent 86

    		SARS-CoV Infection
    Antiviral agent 86 is an anti-coronavirus agent. Antiviral agent 86 acts as a binder of coronavirus non-structural protein 15 (nsp15), with a Ka value of 67 μM against human targets. Antiviral agent 86 inhibits the replication of HCoV-229E and SARS-CoV-2. Antiviral agent 86 exerts inhibitory effects at the post-entry lifecycle stage of coronaviruses in host cells and inhibits the formation of viral double-stranded RNA (dsRNA). Antiviral agent 86 exhibits an additive antiviral effect when used in combination with GS-441524. Antiviral agent 86 can be used in studies related to coronavirus infections .
    Antiviral agent 86
  • HY-P11698
    Guanidino-G-Clamp-PNA

    		DNA Alkylator/Crosslinker Transthyretin (TTR) Cancer
    Guanidino-G-Clamp-PNA is a highly efficient sequence-specific RNA binder and gene silencer. Guanidino-G-Clamp-PNA precisely targets such targets as miR-155 or transthyretin (TTR) mRNA through base pairing: the former regulates tumor-related signaling pathways by reducing microRNA activity, while the latter inhibits the translation of harmful proteins via steric hindrance. Guanidino-G-Clamp-PNA effectively stabilizes DNA/RNA duplexes, induces cancer cell apoptosis, and suppresses tumor growth. In addition, Guanidino-G-Clamp-PNA can be conjugated with targeting ligands to improve tissue-specific delivery and reduce in vivo adverse reactions, and it can also enhance the splicing regulation efficacy of other oligonucleotide platforms (such as PMO) when integrated into them. Guanidino-G-Clamp-PNA is applicable to the research of various diseases including diffuse large B-cell lymphoma and hereditary transthyretin-related amyloidosis .
    Guanidino-G-Clamp-PNA

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: